Top Reasons HCPs in Academic and Community Settings Did Not Offer Therapies to Eligible Patients^1,a,b

Logistical challenges and side effect monitoring were the top reasons why BsAbs were not offered to patients in both settings; financial challenges were also cited by community setting HCPs

Top reasons CAR T-cell therapy was not offered included logistical challenges (both settings), delay in starting treatment in academic settings, and limited practice capabilities in community settings

^aLanguage of some responses has been simplified from survey prompt. ^bTop reason defined as any reason that was given by more than 25% of HCPs in community settings during the survey.

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional.

Reference

1. Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.